Zobrazeno 1 - 10
of 14
pro vyhledávání: '"S. A. Limentani"'
Autor:
José A. García-Sáenz, Monika Patre, J. Xu, Jenny C. Chang, P. Fumoleau, SL de Haas, Miguel Martín, S. A. Limentani, Alexander Strasak, Joan Albanell, J. A. Dewar, Mario Campone
Publikováno v:
Annals of Oncology. 27:1249-1256
Background Trastuzumab emtansine (T-DM1) exhibited enhanced antitumor activity when combined with docetaxel or pertuzumab in preclinical studies. This phase Ib/IIa study assessed the feasibility of T-DM1 + docetaxel in patients with human epidermal g
Autor:
J. A. Dewar, Joan Albanell, Monika Patre, Alexander Strasak, M. Martin, Jenny C. Chang, S. A. Limentani, José A. García-Sáenz
Publikováno v:
Cancer Research. 73:P4-12
Introduction Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate comprising trastuzumab, a stable linker, and DM1 (a microtubule inhibitor). T-DM1 prolonged PFS and OS compared with standard therapy in a phase 3 study in patients with human
Autor:
Monika Patre, F Branle, José A. García-Sáenz, Alexander Strasak, Pierre Fumoleau, S. A. Limentani, J. A. Dewar, M. Martin, Joan Albanell
Publikováno v:
Cancer Research. 72:P5-18
Introduction: Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate comprising trastuzumab, a stable linker, and DM1 (a microtubule inhibitor). In 2 randomized trials in patients (pts) with HER2-positive metastatic breast cancer (MBC), T-DM1 si
Autor:
L A Kachnic, L D Case, Joel E. Tepper, C Partensky, Edward A. Levine, Susan A. Melin, Girish Mishra, L Descos, S A Limentani, F Mornex, A W Blackstock
Publikováno v:
British Journal of Cancer
The safety and efficacy of gemcitabine and concurrent radiation to the upper abdomen followed by weekly gemcitabine in patients with resected pancreatic cancer was determined. Patients with resected adenocarcinoma of the pancreas were treated with in
Autor:
S, Jagannath, B, Barlogie, J, Berenson, D, Siegel, D, Irwin, P G, Richardson, R, Niesvizky, R, Alexanian, S A, Limentani, M, Alsina, J, Adams, M, Kauffman, D-L, Esseltine, D P, Schenkein, K C, Anderson
Publikováno v:
British journal of haematology. 127(2)
In a phase 2 open-label study of the novel proteasome inhibitor bortezomib, 54 patients with multiple myeloma who had relapsed after or were refractory to frontline therapy were randomized to receive intravenous 1.0 or 1.3 mg/m(2) bortezomib twice we
Publikováno v:
American journal of hematology. 51(4)
Investigation of recurrent venous thromboembolic events in a 46-year-old man with progressive IgG kappa (total serum IgG, 74.3 mg/ml) multiple myeloma revealed profound reductions in free protein S (PS) antigen (0.l U/ml) and PS activity (0.33 U/ml).
Publikováno v:
Thrombosis and haemostasis. 73(4)
This study employed sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis and immunoblotting to assess the purity of seven high purity factor IX concentrates: Aimafix (Aima), AlphaNine-SD (Alpha Therapeutic), Factor IX VHP (Bi
Publikováno v:
Blood. 84(1)
Autor:
Les H. Brail, I. Gueorguieva, J. R. Infante, Johanna C. Bendell, D. Satonin, A. P. Anderson, Steven J.M. Jones, S. A. Limentani, H. A. Burris
Publikováno v:
Journal of Clinical Oncology. 29:e13575-e13575
e13575 Background: AKT, a serine/threonine kinase, is constitutively activated in a wide variety of cancer types and activation of the PI3K/AKT pathway is frequently associated with increased neovascular formation and metastasis as well as resistance
Autor:
V. Agrapart, F. Binlich, Ahmad Awada, Véronique Diéras, S. A. Limentani, T Luu, Richat Abbas, D. Hershman, Antonio Llombart, L.Y. Dirix, Luis Manso, J. Beck, C. Germa, Christine Powell
Publikováno v:
Cancer Research. 69:5095-5095
Background: The irreversible pan-ErbB tyrosine kinase inhibitor neratinib (HKI-272) potently blocks downstream signaling of the ErbB1, -2, and -4 receptors and has demonstrated antitumor activity in patients with ErbB2+ breast cancer (BC). Vinorelbin